February 20, 2025 07:30 AM ESTUpdated 07:49 AM

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Max Gelman

Senior Editor

BridgeBio revealed Thursday that prescriptions for its recently approved rare heart disease drug Attruby substantially beat analyst projections — an update that is likely to further …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Roche no longer wants to be where ‘DNA sequencing goes to die’

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BridgeBio’s heart disease drug Attruby sails past prescription estimates